Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

PPD Plans Major Suzhou Lab to Offer China Drug Development Services

publication date: Oct 15, 2020

PPD, a global CRO, announced plans to build a new laboratory in Suzhou to support China drug development. The 67,000-square-foot facility, which will offer bioanalytical, biomarker and vaccine services, will hire an additional 350 staff members. Planned for completion in 2021, the facility will be located in the Suzhou New District, Jiangsu Province. PPD already operates a Shanghai central lab that offers safety and efficacy testing, custom specimen collection kits and biorepository services for clinical trials. More details....

Stock Symbol: (NSDQ: PPD)

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here